News for Healthier Living

ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma

In a first-of-its-kind randomized trial, Dana-Farber Cancer Institute researchers found that teclistamab may significantly improve outcomes for patients with high-risk smoldering multiple myeloma, a precursor condition that can progress to active cancer.

June 15, 2026


June 15 2026

June 14 2026

June 13 2026

June 12 2026

June 11 2026

June 10 2026

June 9 2026

June 8 2026

June 7 2026

June 5 2026

June 4 2026

June 3 2026

June 2 2026

June 1 2026